Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

(2016) Morie A. Gertz et al.   JOURNAL OF CLINICAL ONCOLOGY

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium

(2015) Isabelle Lousada et al.   ADVANCES IN THERAPY

Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial

(2015) Vaishali Sanchorawala et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study

(2015) Anita D'Souza et al.   JOURNAL OF CLINICAL ONCOLOGY

Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens

(2015) Tilmann Bochtler et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component

(2015) Duncan B. Richards et al.   NEW ENGLAND JOURNAL OF MEDICINE

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis

(2014) G. Palladini et al.   BLOOD

Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial

(2014) Xianghua Huang et al.   BMC Medicine

Guidelines on the management of AL amyloidosis

(2014) Ashutosh D. Wechalekar et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment

(2013) Morie A. Gertz   AMERICAN JOURNAL OF HEMATOLOGY

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

(2013) A. D. Wechalekar et al.   BLOOD

Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis

(2013) Taxiarchis V. Kourelis et al.   JOURNAL OF CLINICAL ONCOLOGY

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis

(2012) M A Gertz et al.   BONE MARROW TRANSPLANTATION

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

(2012) Giovanni Palladini et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis

(2012) H Landau et al.   LEUKEMIA

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

(2011) M. T. Cibeira et al.   BLOOD

Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego)

(2007) Angela Dispenzieri et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION